On January 7, 2026 Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity, reported successful completion of a non-human primates toxicology study (the "Study") of IM1240, a tri-specific antibody from its CAPTN-3 platform that targets 5T4, a tumor-specific antigen expressed on multiple solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Study demonstrated that IM1240’s proprietary capping technology enabled dosing at levels up to 300-fold higher than a non-capped comparator, with significantly reduced immune-related toxicity, including minimal cytokine release. These results highlight the unique safety profile of this approach, which may address a key limitation of certain current T cell engagers, where cytokine release syndrome can restrict dosing.

"In the Study, IM1240 demonstrated a favorable safety and tolerability profile, with hematologic findings that align with its expected pharmacodynamic effects on immune activation. The CD3 capping design of IM1240 showed clear differentiation compared with the non-capped comparator, IM1222, enabling a significant reduction in immune-related effects, including cytokine release, which remained modest, even at doses up to 300-fold higher than those of the non-capped antibody," stated Gil Efron, CEO of Purple Biotech. "Purple Biotech continues to deliver on its stated milestones and we believe that collectively, these data provide translational guidance that may inform optimal dose selection, dosing strategy, and safety monitoring plans for the next phase of advanced toxicological assessments. We are working to advance IM1240 toward first-in-human studies as efficiently as possible and expect to provide updates on our progress over the course of 2026."

IM1240 demonstrated a favorable pharmacokinetic (PK) profile in the Study, characterized by increased systemic exposure and a prolonged circulating half-life. PK analyses showed dose-dependent and proportional increases in exposure, as reflected by both AUC and Cmax. The Company believes these findings support dose-exposure relationship and provide proof of concept for the capping design and albumin incorporation as a contributor to IM1240’s favorable PK profile. In addition, efficacy observed in vivo in tumor-bearing mice occurred at exposures meaningfully lower than those achieved in the Study, further supporting IM1240’s advantageous therapeutic window.

About the CAPTN-3 Platform

CAPTN-3, Purple Biotech’s lead program, is a platform of capped tri-specific antibodies that simultaneously target tumor-associated antigens while engaging both T cells and NK cells. Proprietary capping technology confines immune activation to the tumor microenvironment by masking the CD3-binding arm in circulation and activating it only at the tumor site, significantly expanding the therapeutic window versus conventional T-cell engagers. The platform’s lead candidates, IM1240 (targeting 5T4) and IM1305 (targeting TROP2), are in preclinical development.

(Press release, Purple Biotech, JAN 7, 2026, View Source [SID1234661809])

On January 7, 2026 InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, reported a global strategic collaboration and licensing agreement, and equity investment, with Eli Lilly and Company ("Lilly") to discover novel oncology treatments using InduPro’s proximity-guided platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, the two companies will collaborate on up to three targets, for a total deal value of up to approximately $950M. Lilly will also make an equity investment in InduPro.

By leveraging Tumor Associated Proximity Antigens (TAPAs), surface antigens that are spatially co-localized and often functionally linked to tumor-associated antigens (TAAs) within the tumor microenvironment, the companies will use InduPro’s proximity-based platform to discover novel, disease-specific protein-target pairs. This strategy is designed to enable new therapeutic approaches for bispecific antibody drug conjugates (ADCs) and multispecific T-cell engagers, offering improved safety, potency, and tumor selectivity.

"Our partnership with Lilly underscores a shared commitment to advancing a new generation of tumor-selective medicines guided by the spatial biology of cancer," said Prakash Raman, PhD, CEO of InduPro. "TAPAs represent a fundamentally new way to think about tumor antigens, and we’re thrilled that Lilly shares our vision of leveraging proximity-based biology to enable precision multi-specific therapeutics. We believe this partnership reflects growing confidence in our differentiated, proximity-guided approach to tumor targeting and its promise to improve the design and performance of ADCs and TCEs."

Through the agreement, Lilly will gain access to InduPro’s proprietary AI/ML-enabled membrane interactomics (MInt) platform. InduPro will lead early discovery efforts, applying its proximity-guided platform to identify co-target pairs and advance bispecific and multispecific antibody programs emerging from the collaboration.

(Press release, InduPro, JAN 7, 2026, View Source [SID1234661824])

On January 7, 2026 Amgen (NASDAQ:AMGN) reported it will present at the 2026 J.P. Morgan Healthcare Conference at 3:45 p.m. PT on Monday, January 12, 2026. Robert A. Bradway, chairman and chief executive officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast, as with other selected presentations regarding developments in Amgen’s business given by management at certain investor and medical conferences, can be found on Amgen’s website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen’s Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

(Press release, Amgen, JAN 7, 2026, View Source [SID1234661794])

On January 7, 2026 RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, reported that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the 44thAnnual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 2:15 p.m. Pacific Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the live webcast or subsequent archived recording of the presentation, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.

(Press release, RAPT Therapeutics, JAN 7, 2026, https://investors.rapt.com/news-releases/news-release-details/rapt-therapeutics-present-44th-annual-jp-morgan-healthcare [SID1234661810])

On January 7, 2026 Volastra Therapeutics, a clinical-stage biotechnology company pioneering first-in-class therapies targeting chromosomal instability (CIN) in cancer, reported a significant expansion of its clinical development program driven by encouraging clinical data from its lead KIF18A inhibitor (KIF18Ai), a key investigational CIN-targeted cancer therapy. The company also highlighted continued advancement across its strategic pipeline and the appointment of Timothy Bowler, M.D., Ph.D., as its new Chief Medical Officer, strengthening its leadership team as it executes on key value-inflection milestones.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"These developments represent a meaningful step forward for Volastra as we continue to build a differentiated oncology company focused on chromosomal instability," said David Southwell, Chief Executive Officer of Volastra Therapeutics. "The strength of the emerging clinical data from our KIF18Ai program reinforces our conviction in CIN as a compelling therapeutic target and supports the expansion of our clinical strategy. With continued progress across our pipeline and the addition of our highly experienced Chief Medical Officer, we are well-positioned to execute on key upcoming milestones and create long-term value for patients and shareholders."

In addition to the company’s progress with its KIF18Ai ovarian cancer clinical program:

Expansion into New Tumor Types: It is also extending its Phase 1/2 program beyond ovarian cancer, with additional efficacy data from expansion cohorts expected in the first half of 2026.
KIF18Ai Combination Trials: The company is advancing new combination therapy studies with standards of care based on synergistic efficacy with taxanes in preclinical studies. Volastra plans to initiate its first combination trial in the first quarter of 2026, evaluating a KIF18Ai in combination with standard-of-care chemotherapy in patients with ovarian, lung, and breast cancers. Initial safety data are anticipated in the second quarter, with efficacy data expected to emerge in the second half of the year.
Biomarker Approach: In parallel, the company will continue to advance its biomarker identification strategy to predict KIF18Ai response, with results expected throughout the first half of 2026.
FDA Regulatory Update: Volastra also anticipates an End-of-Phase meeting with the FDA in the second half of 2026 to discuss potential registrational trials, reflecting the continued clinical momentum of the program.
These initiatives build on VLS-1488’s Phase 1 clinical results and follow the program’s FDA Fast Track designation in platinum-resistant ovarian cancer. To date, more than 120 patients have been treated with VLS-1488, which has been well tolerated across all dose levels with no dose-limiting toxicities observed. The company has demonstrated a clear dose-response across dose levels, with strong early efficacy and a favorable safety profile in platinum-resistant ovarian cancer. Notably, VLS-1488 has also demonstrated durable clinical benefit, with approximately half of patients with squamous non-small cell lung cancer remaining on therapy beyond six months.

To support its pipeline growth, Volastra has appointed Timothy Bowler, M.D., Ph.D., as Chief Medical Officer. He will oversee the expanded clinical program and drive the execution of the company’s development strategy. Dr. Bowler succeeds Dr. Scott Druttman, who is leaving Volastra to pursue other opportunities.

"Tim has been instrumental in driving our clinical progress, and we are delighted to have him step into the CMO role," said Mr. Southwell. "His expertise in oncology drug development will be invaluable as we advance our pipeline and strive to deliver CIN-targeted therapies to patients."

Dr. Bowler, a board-certified medical oncologist and experienced drug developer, previously served as Volastra’s Vice President of Clinical Development. Prior to joining Volastra in 2023, Dr. Bowler was Global Clinical Lead in oncology at Pfizer, and previously served at Regeneron and Memorial Sloan Kettering Cancer Center. In his new role, he will spearhead all clinical strategy and operations, guiding the KIF18Ai program through its next phase of growth and advancing Volastra’s broader clinical portfolio.

"Volastra’s innovative approach to targeting chromosomal instability has tremendous potential to benefit patients," said Timothy Bowler, M.D., Ph.D., Chief Medical Officer of Volastra. "Our focus now is executing a disciplined development plan that builds on monotherapy activity while expanding the reach of KIF18Ai through combinations and biomarker-guided approaches."

(Press release, Volastra Therapeutics, JAN 7, 2026, View Source [SID1234661825])